Sugi Predict

Sugi Predict / Compounds / SCHEMBL190497

SCHEMBL190497

SCHEMBL190497

CC(C)(C)OC(=O)N1CCC(Oc2ccnc(Cl)c2)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 11/20 0.53
▸ NPBWR1 P48145 1/20 0.48
▸ MCHR1 Q99705 1/20 0.48
▸ HRH3 Q9Y5N1 1/20 0.48
▸ CHEK2 O96017 1/20 0.48
▸ POLB P06746 1/20 0.46
▸ CACNB4 O00305 1/20 0.46
▸ CACNA1A O00555 1/20 0.46
▸ CACNA1G O43497 1/20 0.46
▸ CACNG3 O60359 1/20 0.46
▸ CACNA1F O60840 1/20 0.46
▸ CACNA1H O95180 1/20 0.46
▸ CACNB3 P54284 1/20 0.46
▸ CACNA2D1 P54289 1/20 0.46
▸ CACNG7 P62955 1/20 0.46
▸ CACNA1B Q00975 1/20 0.46
▸ CACNA1D Q01668 1/20 0.46
▸ CACNB1 Q02641 1/20 0.46
▸ CACNG1 Q06432 1/20 0.46
▸ CACNB2 Q08289 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29495616 1.00 GPR119 (0.53) GPR119NPBWR1MCHR1HRH3CHEK2
SCHEMBL18318752 0.88 GPR119 (0.56) GPR119CHEK2CACNB4CACNA1ACACNA1G
SCHEMBL16473494 0.87 GPR119 (0.54) GPR119NPBWR1MCHR1HRH3CHEK2
SCHEMBL190408 0.87 CHEK2 (0.51) GPR119CHEK2PDE4B
SCHEMBL29615477 0.86 GPR119 (0.53) GPR119HRH3CHEK2PDE4APDE4B
SCHEMBL29079775 0.86 GPR119 (0.53) GPR119HRH3CHEK2PDE4APDE4B
SCHEMBL20507845 0.86 GPR119 (0.53) GPR119HRH3CHEK2PDE4APDE4B
SCHEMBL13462815 0.86 GPR119 (0.53) GPR119HRH3CHEK2PDE4APDE4B
SCHEMBL21144113 0.85 GPR119 (0.54) GPR119NPBWR1MCHR1HRH3CHEK2
SCHEMBL20779786 0.85 GPR119 (0.53) GPR119NPBWR1MCHR1HRH3CHEK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250026764-A1 POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 UNIV VANDERBILT (US) 2025-01-23 — — US disclosed
US-20230348490-A1 POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 VANDERBILT UNIVERSITY 2023-11-02 — — US disclosed
US-20230348490-A1 POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 VANDERBILT UNIVERSITY 2023-11-02 — — US disclosed
US-20230348490-A1 POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 VANDERBILT UNIVERSITY 2023-11-02 — — US disclosed
EP-4186910-A1 POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 Vanderbilt University (US) 2023-05-31 — — EP disclosed
EP-4186910-A1 POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 Vanderbilt University (US) 2023-05-31 — — EP disclosed
CN-116178391-A Forward allosteric modulators of muscarinic acetylcholine receptor M4 范德比尔特大学 2023-05-30 — — CN disclosed
CN-109310668-B Positive allosteric modulators of muscarinic acetylcholine receptor M4 范德比尔特大学 2023-01-24 — — CN disclosed
US-20230014109-A1 POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 VANDERBILT UNIVERSITY 2023-01-19 — — US disclosed
US-20230014109-A1 POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 VANDERBILT UNIVERSITY 2023-01-19 — — US disclosed
US-7615643-B2 3-[((1R)-1-{2-Chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl}ethyl)oxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-2-thiophenecarboxamide; polo like kinase enzyme inhibitors; anticarcinogenic agents for treating cancer SMITHKLINE BEECHAM CORPORATION (US) 2009-11-10 — — US disclosed
US-7615643-B2 3-[((1R)-1-{2-Chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl}ethyl)oxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-2-thiophenecarboxamide; polo like kinase enzyme inhibitors; anticarcinogenic agents for treating cancer SMITHKLINE BEECHAM CORPORATION (US) 2009-11-10 — — US disclosed
US-20090247526-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2009-10-01 — — US disclosed
EP-2065369-A1 UREA COMPOUND OR SALT THEREOF Astellas Pharma Inc. (JP) 2009-06-03 — — EP disclosed
US-20090124615-A9 Benzimidazole Thiophene Compounds KUNTZ KEVIN 2009-05-14 — — US disclosed
US-20090124615-A9 Benzimidazole Thiophene Compounds KUNTZ KEVIN 2009-05-14 — — US disclosed
US-20080300247-A1 Benzimidazole Thiophene Compounds KUNTZ KEVIN 2008-12-04 — — US disclosed
US-20080300247-A1 Benzimidazole Thiophene Compounds KUNTZ KEVIN 2008-12-04 — — US disclosed
EP-1986645-A1 GLUCOKINASE ACTIVATORS Array Biopharma, Inc. (US) 2008-11-05 — — EP disclosed
WO-2007089512-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2007-08-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230014109-A1 POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 CHRM4, CHRM5, CHRM2 GPR119 220/4885NPBWR1 1161/4885MCHR1 179/4885
US-20230348490-A1 POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 CHRM4, CHRM5, CHRM2 GPR119 220/4885NPBWR1 1161/4885MCHR1 179/4885
US-20250026764-A1 POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 CHRM4, CHRM5, CHRM2 GPR119 220/4885NPBWR1 1161/4885MCHR1 179/4885
US-20090124615-A9 Benzimidazole Thiophene Compounds ABCB1, CYP3A5, ABCG2 GPR119 2308/4885NPBWR1 4785/4885MCHR1 4706/4885
US-20090247526-A1 GLUCOKINASE ACTIVATORS GCKR, GCK, GALK1 GPR119 5/4885NPBWR1 2937/4885MCHR1 3842/4885
US-20080300247-A1 Benzimidazole Thiophene Compounds ABCB1, CYP3A5, ABCG2 GPR119 2308/4885NPBWR1 4785/4885MCHR1 4706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.